Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs.




Hepatera is a Russian biotechnology company founded in 2011. The main activity of the company is the search for and evaluation of promising drug candidates, as well as development and bringing to the Russian market safe and effective drugs for the treatment of liver diseases. First product (Myrcludex B) is aimed at the treatment of chronic hepatitis B and D. Myrcludex B is based on the research of the University Ruprecht-Karls-Universität Heidelberg, and is being developed in the framework of international cooperation with the biotechnology company MYR, GmbH (Germany).

Since December 2011 Hepatera has become resident of Biomedical cluster of Skolkovo innovation center.